Dr Agarwal Eye Hospital Merger: 2 Shares Become 23 Dr Agarwal Health Care Shares

Dr Agarwal's Eye Hospital Limited (BSE: 526783) is being amalgamated into Dr Agarwal's Health Care Limited (NSE: AGARWALEYE, BSE: 544350). The scheme becomes effective on November 1, 2026, while November 18, 2026 is the record date for deciding which Eye Hospital shareholders receive consideration shares. The approved ratio is unusually large in headline terms: 23 Dr Agarwal Health Care shares for every 2 Dr Agarwal Eye Hospital shares. The old Eye Hospital company is dissolved under the scheme, so shareholders should expect their economic holding to move into the already-listed Health Care company.

Which Dr Agarwal company survives the merger?

This merger can be confusing because both companies carry almost the same brand name and both have been listed entities.

Dr Agarwal's Eye Hospital Limited, commonly referred to as AEHL, is the transferor company. Dr Agarwal's Health Care Limited, or AHCL, is the transferee company and is the entity that survives the amalgamation.

The NCLT Chennai Bench sanctioned the scheme on September 30, 2026. After completion of the required filings and conditions, the companies fixed November 1, 2026 as the effective date. Under the scheme, AEHL stands dissolved without being wound up from the effective date, while AHCL continues as the listed operating company.

For shareholders, however, the crucial date is different. November 18, 2026 is the record date used to identify the eligible AEHL shareholders who will receive AHCL shares.

That distinction matters because "effective date" and "record date" serve different purposes. November 1 gives legal effect to the amalgamation; November 18 determines the shareholder entitlement for the share exchange.

How many Dr Agarwal Health Care shares will you receive?

The approved share exchange ratio is:

23 Dr Agarwal Health Care shares for every 2 Dr Agarwal Eye Hospital shares

AHCL shares have a face value of ₹1 each, while the old AEHL shares have a face value of ₹10 each. Face value should not be confused with market value; the exchange ratio itself is the binding entitlement under the scheme.

A shareholder holding an even number of AEHL shares receives a whole-number result under the 23:2 ratio. An odd-number holding creates a fractional entitlement. For example, one AEHL share corresponds economically to 11.5 AHCL shares.

The company has confirmed that no fractional equity shares will be issued directly. Fractions will be consolidated through a trustee, sold on the stock exchanges within 90 days from the allotment date, and the net proceeds—after applicable costs, expenses and withholding taxes—will be distributed to eligible shareholders according to their fractional entitlement.

When will the new AGARWALEYE shares appear in demat?

Eligible demat shareholders do not need to submit a separate merger application. The new Dr Agarwal Health Care shares are to be allotted in dematerialised form and credited directly to the beneficiary demat account after the necessary regulatory and stock-exchange approvals are obtained.

That means the November 18 record date is not a guaranteed November 18 credit date. It decides who is eligible. The actual allotment and credit follow the corporate-action process.

This is important because the old AEHL legal entity is being dissolved under the scheme while the replacement shares may appear later in the investor's broker portfolio. A temporary period in which the old holding no longer behaves like a normal security and the replacement AHCL quantity is not yet visible should not automatically be interpreted as missing wealth.

The surviving company, Dr Agarwal's Health Care Limited, is already listed under NSE: AGARWALEYE and BSE: 544350. The consideration shares issued under the merger will still need the applicable regulatory/exchange process before they are credited and available in the ordinary manner.

The company has said a separate communication or advice will be sent to eligible shareholders after allotment and credit.

What happens if you hold Dr Agarwal Eye Hospital shares in physical form?

Physical shareholders need to pay particular attention to the company's latest communication.

The replacement AHCL shares are to be issued only in dematerialised form. If an eligible shareholder still holds AEHL in physical certificates on the record date, the consideration shares will initially be credited to a dedicated trustee demat account. They will remain there until the shareholder submits and verifies the required demat details and documents.

The company has therefore explicitly encouraged physical shareholders to complete dematerialisation before November 18, 2026.

For an ordinary demat holder, the practical check is simpler: ensure the DP ID and Client ID are active and correctly maintained with the Depository Participant. If the merger shares are later not visible despite confirmed eligibility, the first useful comparison is the underlying depository record rather than only the broker app's main holdings screen.

Does the 23-for-2 ratio mean an instant profit?

No. A large numerical share ratio should not be read as a free 11.5-times increase in wealth.

AEHL and AHCL have different outstanding share counts, face values and market prices. The merger ratio determines how ownership in the transferor is converted into ownership in the transferee. The correct post-merger comparison is the value of the AHCL shares received against the economic value of the old AEHL holding—not the raw number of shares alone.

For example, an investor with 10 AEHL shares will receive 115 AHCL shares under the scheme. That does not mean the investment has automatically multiplied 11.5 times. It means each old AEHL share is being converted into 11.5 AHCL shares based on the approved valuation and structure of the merger.

The same principle applies to other share-swap mergers. Credivant's coverage of the Markolines merger explains why the share ratio must be read together with the companies' market values rather than as a standalone return.

What should shareholders watch next?

There are now four dates or stages that matter.

The scheme effective date is November 1. The record date is November 18. After that comes the actual allotment and demat credit of AHCL consideration shares, followed by the applicable exchange approvals for those newly issued shares.

The company has already communicated the record date directly to shareholders, so the event is no longer at the proposal stage. The next high-value update for investors will be confirmation that the consideration shares have been allotted and credited.

Shareholders should therefore avoid searching for a speculative "listing date" before the company or exchanges publish an official notice. Because AHCL is already listed, the relevant question is primarily when the new merger consideration shares are allotted, credited and admitted for normal trading, not when AHCL itself first lists.

Frequently Asked Questions

What is the Dr Agarwal Eye Hospital merger record date?

The record date is November 18, 2026. Eligible Dr Agarwal Eye Hospital shareholders on that date will receive merger consideration shares in Dr Agarwal Health Care.

What is the Dr Agarwal merger share ratio?

The ratio is 23 shares of Dr Agarwal's Health Care Limited for every 2 shares of Dr Agarwal's Eye Hospital Limited held on the record date.

What happens if I hold only 1 Dr Agarwal Eye Hospital share?

One AEHL share corresponds economically to 11.5 AHCL shares. Since fractional shares will not be issued directly, the fractional entitlement is handled through the trustee mechanism and the relevant net sale proceeds are distributed to eligible shareholders.

Will Dr Agarwal Eye Hospital shares disappear after the merger?

Dr Agarwal's Eye Hospital Limited is the transferor company and is dissolved under the scheme. Eligible shareholders receive Dr Agarwal Health Care shares in place of their old economic holding according to the approved 23:2 ratio.

When will the new Dr Agarwal Health Care shares be credited?

The record date only determines eligibility. The new AHCL shares will be allotted and credited after the necessary corporate, regulatory and stock-exchange approvals. An exact credit date should not be assumed until the company confirms allotment.

Which Dr Agarwal stock survives after the merger?

Dr Agarwal's Health Care Limited survives as the transferee and listed company. Its current exchange identifiers are NSE: AGARWALEYE and BSE: 544350.

This article will be updated on the same URL when the allotment and credit status changes.

This article is for informational and educational purposes only and is not a recommendation to buy or sell any security.